Forxiga 5 mg film-coated tablets

DRUG4 trials

Sponsors

University Medical Center Groningen, Universitaetsmedizin Goettingen, Center For Outcomes Research And Clinical Epidemiology S.r.l., Humanitas Mirasole S.p.A.

Conditions

Alport syndromeChronic Kidney DiseaseMyocardial InfarctionType 1 DiabetesType 2 diabetes mellitusdiabetes mellitus

Phase 2

ASPIRE-1: Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial

WithdrawnCTIS2023-504404-28-00

University Medical Center GroningenChronic Kidney Disease, Type 1 Diabetes

Target: 26Updated: 2026-02-03

Phase 3

DOUBLE PRO-TECT Alport: A confirmatory, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the effect of Dapagliflozin on the progression of chronic kidney disease in adolescent and young adult patients with Alport syndrome

RecruitingCTIS2023-508502-18-00

Universitaetsmedizin GoettingenAlport syndrome

Start: 2024-03-19Target: 102Updated: 2025-10-16

Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus

Not yet recruitingCTIS2025-523375-29-00

Humanitas Mirasole S.p.A.diabetes mellitus, Myocardial Infarction

Target: 300Updated: 2026-02-06

Phase 4

Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.

CompletedCTIS2024-518915-20-00

Center For Outcomes Research And Clinical Epidemiology S.r.l.Type 2 diabetes mellitus

Start: 2022-02-16End: 2025-10-02Target: 1167Updated: 2025-09-30

Related Papers

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.

2025-04-0115 citations